Endoscopic Valve Ablation for Posterior Urethral Valves (PUV)
Treatment for Urogenital Congenital Anomalies
Effectiveness
90%
Safety Score
65%
Clinical Trials
250
Participants
8K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
65
DangerousModerateSafe
Treatment Details
Time to Effect
Immediate relief of obstruction, renal function improvement over months
Treatment Duration
Single endoscopic procedure, lifelong follow-up for renal/bladder function
Evidence Quality
MODERATEConfidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$300
Monitoring:$2,000
Side Effect Mgmt:$1,000
Total Annual:$10,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENTQALYs Gained
2
Outcome-Based Costs
Cost per Responder
$11,111
Comparison vs Catheter Diversion / No Ablation
Cost Difference
$0/year
Same cost
QALY Difference
+2.00 QALYs
Better outcomes
Dominance
DOMINATESBetter + cheaper
Endoscopic Valve Ablation for Posterior Urethral Valves (PUV) Outcomes
for Urogenital Congenital Anomalies
Efficacy Outcomes
Overall Effectiveness
+90%
Response Rate
+90%
Common Side Effects
Urethral stricture/scarring
+10%
Bladder dysfunction (neurogenic-like)
+30%
Persistent vesicoureteral reflux
+25%
Urinary tract infection
+3%
Failure to completely ablate valves (requiring repeat)
+8%
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov